This study is in progress, not accepting new patients
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Lead Scientist at UCSF
- Peter Ljubenkov
Dr. Peter A. Ljubenkov is a behavioral neurologist who specializes in caring for patients experiencing memory, language and behavioral changes due to neurological conditions, such as Alzheimer's disease, Lewy body dementia and other causes of dementia.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Alector Inc.
- Phase 2 research study
- Study Type
- Expecting 40 study participants
- Last Updated